Usama Gergis, MD

home / authors / usama-gergis-md

Articles

Gergis Explains the Differences Between Acute and Chronic GVHD

Gergis Explains the Differences Between Acute and Chronic GVHD

Usama Gergis, MD
February 16th 2021

Usama Gergis, MD, MBA, reviewed that difference in acute and chronic graft-versus-host disease and the treatment available for each

A 61-Year-Old Man With Acute Graft-Versus-Host Disease

A 61-Year-Old Man With Acute Graft-Versus-Host Disease

Usama Gergis, MD
April 24th 2020

Usama Gergis, MD, presents the case of a 61-year old man with GvHD, and provides an overview of available treatment options for similar patients, with consideration of the REACH1, REACH2, and GRAVITAS-301 trial regimens.

The Future of GVHD Management

The Future of GVHD Management

Usama Gergis, MD
April 24th 2020
Phase 3 Trials: REACH2 and GRAVITAS-301

Phase 3 Trials: REACH2 and GRAVITAS-301

Usama Gergis, MD
April 24th 2020
REACH1 Regimen: Steroid Combination and Adverse Events

REACH1 Regimen: Steroid Combination and Adverse Events

Usama Gergis, MD
April 24th 2020
Phase 2 REACH1 Overview

Phase 2 REACH1 Overview

Usama Gergis, MD
April 24th 2020
Steroid-Dependent Versus Steroid-Refractory Graft-Versus-Host Disease

Steroid-Dependent Versus Steroid-Refractory Graft-Versus-Host Disease

Usama Gergis, MD
April 24th 2020
A 61-Year-Old Man With Graft-Versus-Host Disease

A 61-Year-Old Man With Graft-Versus-Host Disease

Usama Gergis, MD
April 24th 2020

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
Published: July 24th 2024 | Updated: July 27th 2024
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
Poll: How Would You Treat a Patient With NSCLC and an EGFR Exon 20 Insertion Mutation?
Published: March 8th 2023 | Updated: July 27th 2024
Poll: How Would You Treat a Patient With NSCLC and an EGFR Exon 20 Insertion Mutation?
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 6th 2023 | Updated: July 27th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Oral SERDs Provide a Stronger Option in ESR1+ Advanced Breast Cancer
Published: January 12th 2024 | Updated: July 27th 2024
Oral SERDs Provide a Stronger Option in ESR1+ Advanced Breast Cancer
Long-Term Quality of Life Remains Positive for Transplant Patients, Regardless of Donor Match
Published: June 18th 2024 | Updated: July 27th 2024
Long-Term Quality of Life Remains Positive for Transplant Patients, Regardless of Donor Match